INVIVYD INC.
NASDAQ: IVVD (Invivyd, Inc.)
Last update: 2 hours ago0.822
0.01 (0.69%)
| Previous Close | 0.817 |
| Volume | 7,129,025 |
| Price / Earnings (Forward) | 44.64 |
| Price / Sales | 4.26 |
| Price / Book | 1.50 |
| 52 Weeks Range |
| Operating Margin (TTM) | -149.70% |
| Diluted EPS (TTM) | -1.19 |
| Total Debt/Equity (MRQ) | 1.65% |
| Current Ratio (MRQ) | 1.53 |
| Operating Cash Flow (TTM) | -141.41 M |
| Levered Free Cash Flow (TTM) | -65.66 M |
| Return on Assets (TTM) | -57.84% |
| Return on Equity (TTM) | -122.69% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Invivyd, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.0 |
| Average | -0.50 |
|
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 41.18% |
| % Held by Institutions | 66.10% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Jupiter Topco Llc | 30 Jun 2026 | 34,173,104 |
| Janus Henderson Group Ltd. | 31 Mar 2026 | 33,094,330 |
| Bvf Inc/Il | 30 Jun 2026 | 28,165,000 |
| Maverick Capital Ltd | 30 Jun 2026 | 18,970,913 |
| Perceptive Advisors Llc | 30 Jun 2026 | 18,490,636 |
| M28 Capital Management Lp | 30 Jun 2026 | 9,248,250 |
| Saturn V Capital Management Lp | 30 Jun 2026 | 8,392,288 |
| Soleus Capital Management, L.P. | 30 Jun 2026 | 7,708,727 |
| Morgan Stanley | 30 Jun 2026 | 5,730,948 |
| Siren, L.L.C. | 30 Jun 2026 | 5,000,000 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |